207 related articles for article (PubMed ID: 27816996)
1. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
5. The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo.
Sak M; Williams BJ; Zumbar CT; Teer L; Al-Kawaaz MNG; Kakar A; Hey AJ; Wilson MJ; Schier LM; Chen J; Lehman NL
Cancer Chemother Pharmacol; 2023 Feb; 91(2):191-201. PubMed ID: 36694044
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
7. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
Zumbar CT; Usubalieva A; King PD; Li X; Mifsud CS; Dalton HM; Sak M; Urio S; Bryant WM; McElroy JP; Farmer G; Lehman NL
J Neurooncol; 2018 May; 137(3):481-492. PubMed ID: 29396807
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.
Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E
Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026
[TBL] [Abstract][Full Text] [Related]
10. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.
Van Brocklyn JR; Wojton J; Meisen WH; Kellough DA; Ecsedy JA; Kaur B; Lehman NL
Cancer Res; 2014 Oct; 74(19):5364-70. PubMed ID: 25106428
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
[TBL] [Abstract][Full Text] [Related]
13. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
14. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
17. The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Hong X; O'Donnell JP; Salazar CR; Van Brocklyn JR; Barnett KD; Pearl DK; deCarvalho AC; Ecsedy JA; Brown SL; Mikkelsen T; Lehman NL
Cancer Chemother Pharmacol; 2014 May; 73(5):983-90. PubMed ID: 24627220
[TBL] [Abstract][Full Text] [Related]
18. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
19. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]